1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Financials
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 114 126353 422318 544196 614--
Enterprise Value (EV)2 109 822348 931312 303190 244188 035181 133
P/E ratio 116x216x97,9x43,5x31,6x23,5x
Yield ------
Capitalization / Revenue 28,6x63,0x31,0x13,1x9,52x7,12x
EV / Revenue 27,6x62,2x30,4x12,7x9,10x6,56x
EV / EBITDA 65,7x142x68,0x30,8x22,6x16,2x
Price to Book 8,93x17,2x10,3x5,37x4,54x3,67x
Nbr of stocks (in thousands) 3 883 5784 084 7634 224 1234 218 527--
Reference price (CNY) 29,486,575,446,646,646,6
Announcement Date 03/26/202003/23/202103/22/2022---
1 HKD in Million
2 CNY in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 3 9845 61210 29014 99820 65927 604
EBITDA1 1 6712 4644 5906 1778 31011 147
Operating profit (EBIT)1 1 1562 0083 3274 9926 9359 422
Operating Margin 29,0%35,8%32,3%33,3%33,6%34,1%
Pre-Tax Profit (EBT)1 1 1271 9663 9935 3007 3299 941
Net income1 1 0101 6893 3884 5576 3028 541
Net margin 25,4%30,1%32,9%30,4%30,5%30,9%
EPS2 0,250,400,771,071,471,98
Dividend per Share2 ------
Announcement Date 03/26/202003/23/202103/22/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2
Net sales1 1 9443 6684 4075 8836 2928 658
EBITDA ------
Operating profit (EBIT)1 --1 7731 5531 9722 779
Operating Margin --40,2%26,4%31,3%32,1%
Pre-Tax Profit (EBT) -1 261----
Net income -953-1 546--
Net margin -26,0%-26,3%--
EPS ------
Dividend per Share ------
Announcement Date 09/21/202003/23/202108/23/202103/22/2022--
1 CNY in Million
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 4 3044 4916 2416 3708 58015 482
Leverage (Debt / EBITDA) -2,58x-1,82x-1,36x-1,03x-1,03x-1,39x
Free Cash Flow1 -2 003-4 178-3 106-5612 7975 472
ROE (Net Profit / Equities) 11,6%10,1%12,8%13,2%15,6%17,4%
Shareholders' equity1 8 71116 67426 42134 54340 34249 007
ROA (Net Profit / Asset) 8,93%7,25%9,28%9,84%11,7%13,5%
Assets1 11 31723 28336 49846 29653 78463 039
Book Value Per Share2 3,295,037,308,6810,312,7
Cash Flow per Share2 0,300,440,771,381,742,23
Capex1 3 2116 0256 5085 7134 4543 372
Capex / Sales 80,6%107%63,2%38,1%21,6%12,2%
Announcement Date 03/26/202003/23/202103/22/2022---
1 CNY in Million
2 CNY
Previous periodNext period
Estimates
Key data
Capitalization (HKD) 229 066 020 552
Capitalization (USD) 29 181 239 775
Net sales (CNY) 10 290 050 000
Net sales (USD) 1 527 234 813
Number of employees 9 864
Sales / Employee (CNY) 1 043 192
Sales / Employee (USD) 154 829
Free-Float 84,2%
Free-Float capitalization (HKD) 192 968 898 943
Free-Float capitalization (USD) 24 582 745 602
Avg. Exchange 20 sessions (CNY) 951 821 162
Avg. Exchange 20 sessions (USD) 141 267 964
Average Daily Capital Traded 0,42%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA